State of the art of Smo antagonists for cancer therapy: Advances in the target receptor and new ligand structures

Christian Espinosa-Bustos, Jaime Mella, Jorge Soto-Delgado, Cristian O. Salas

Resultado de la investigación: Contribución a una revistaArtículo de revisión

3 Citas (Scopus)

Resumen

Since the Hedgehog signaling pathway has been associated with cancer, it has emerged as a therapeutic target for cancer therapy. The main target among the key Hedgehog proteins is the GPCR-like Smo receptor. Therefore, some Smo antagonists that have entered clinical trials, including the US FDA-approved drugs vismodegib and sonidegib, to treat basal cell carcinoma and medulloblastoma. However, early resistance of these drugs has spawned the need to understand the molecular bases of this phenomena. We therefore reviewed details about Smo receptor structures and the best Smo antagonist chemical structures. In addition, we discussed strategies that should be considered to develop new, safer generations of Smo antagonists that avoid current clinical limitations.

Idioma originalInglés
Páginas (desde-hasta)617-638
Número de páginas22
PublicaciónFuture Medicinal Chemistry
Volumen11
N.º6
DOI
EstadoPublicada - 1 mar 2019

Áreas temáticas de ASJC Scopus

  • Medicina molecular
  • Farmacología
  • Descubrimiento de medicamentos

Huella Profundice en los temas de investigación de 'State of the art of Smo antagonists for cancer therapy: Advances in the target receptor and new ligand structures'. En conjunto forman una huella única.

  • Citar esto